Axon Enterprise, Inc. (NASDAQ:AXON) Shares Purchased by Geneos Wealth Management Inc.

Geneos Wealth Management Inc. grew its position in shares of Axon Enterprise, Inc. (NASDAQ:AXON) by 630.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,847 shares of the biotechnology company’s stock after purchasing an additional 1,594 shares during the period. Geneos Wealth Management Inc.’s holdings in Axon Enterprise were worth $1,098,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Geode Capital Management LLC boosted its position in Axon Enterprise by 2.0% during the third quarter. Geode Capital Management LLC now owns 1,782,828 shares of the biotechnology company’s stock worth $710,103,000 after acquiring an additional 35,320 shares during the last quarter. Westfield Capital Management Co. LP boosted its holdings in shares of Axon Enterprise by 12.2% during the third quarter. Westfield Capital Management Co. LP now owns 1,175,328 shares of the biotechnology company’s stock worth $469,661,000 after purchasing an additional 127,769 shares during the last quarter. Champlain Investment Partners LLC grew its position in shares of Axon Enterprise by 13.9% in the third quarter. Champlain Investment Partners LLC now owns 682,420 shares of the biotechnology company’s stock valued at $272,695,000 after purchasing an additional 83,265 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in Axon Enterprise by 1.6% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 561,263 shares of the biotechnology company’s stock valued at $224,281,000 after purchasing an additional 9,090 shares during the last quarter. Finally, Groupama Asset Managment purchased a new position in Axon Enterprise during the third quarter worth about $200,000. 79.08% of the stock is currently owned by hedge funds and other institutional investors.

Axon Enterprise Stock Performance

Axon Enterprise stock opened at $604.68 on Tuesday. The company has a debt-to-equity ratio of 0.32, a current ratio of 2.96 and a quick ratio of 2.63. The firm’s fifty day moving average price is $617.75 and its 200 day moving average price is $474.21. The company has a market capitalization of $46.11 billion, a price-to-earnings ratio of 156.25, a price-to-earnings-growth ratio of 6.09 and a beta of 1.04. Axon Enterprise, Inc. has a 12-month low of $247.04 and a 12-month high of $698.67.

Insider Transactions at Axon Enterprise

In other news, Director Michael Garnreiter sold 1,000 shares of the company’s stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $639.69, for a total value of $639,690.00. Following the sale, the director now owns 24,259 shares in the company, valued at approximately $15,518,239.71. This represents a 3.96 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, President Joshua Isner sold 20,000 shares of the stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $606.15, for a total transaction of $12,123,000.00. Following the transaction, the president now directly owns 208,166 shares in the company, valued at $126,179,820.90. The trade was a 8.77 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 50,545 shares of company stock valued at $30,721,337. 6.10% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several analysts have commented on AXON shares. The Goldman Sachs Group lifted their price target on Axon Enterprise from $500.00 to $700.00 and gave the company a “buy” rating in a report on Monday. JMP Securities boosted their target price on shares of Axon Enterprise from $430.00 to $500.00 and gave the company a “market outperform” rating in a report on Thursday, October 31st. Northland Securities increased their price target on shares of Axon Enterprise from $365.00 to $550.00 and gave the stock an “outperform” rating in a research note on Monday, November 11th. Robert W. Baird lifted their price target on shares of Axon Enterprise from $600.00 to $800.00 and gave the company an “outperform” rating in a report on Friday, December 6th. Finally, Morgan Stanley upgraded Axon Enterprise from an “equal weight” rating to an “overweight” rating and upped their price objective for the stock from $500.00 to $700.00 in a report on Tuesday, December 3rd. One analyst has rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $524.85.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.